ONCO · Onconetix, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Because of historical and expected operating losses and net operating cash flow deficits, there is substantial doubt about the Company's ability to continue as a going concern for one year from the issuance of the unaudited condensed consolidated financial statements, which is not alleviated by management's plans.”View the 10-Q filed Aug 13, 2026
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| $645.82K | $815.37K | $2.52M | $58.47K | — | — | |
| $126.6K | $182.46K | $1.47M | $1.19M | — | — | |
| $519.23K | $632.91K | $1.06M | -$1.13M | — | — | |
| — | 77.62% | 41.8% | -1927.93% | — | — | |
| — | — | $154.36K | $1.95M | $4.13M | $1.33M | |
| $8.8M | — | — | — | $9.35M | $2.09M | |
| $8.13M | $7.04M | $11.23M | $14.77M | $9.35M | — | |
| — | — | $709.04K | $36.81K | — | — | |
| — | $15.17K | $731.35K | $43.94K | $6752 | — | |
| $16.83M | $18.49M | $57.54M | $34.91M | $13.48M | $3.42M | |
| — | $35K | $35K | — | — | — | |
| -$16.31M | -$17.86M | -$56.49M | -$36.03M | -$13.48M | -$3.42M | |
| — | -2190.03% | -2237.96% | -61634.47% | — | — | |
| — | -$17.84M | -$55.76M | -$35.99M | -$13.47M | — | |
| $310.95K | $751.01K | $873.43K | $671.63K | — | — | |
| — | $2 | $18 | — | — | — | |
| $6.11M | $3.83M | -$3.25M | -$1.39M | $61.41K | — | |
| -$10.2M | -$14.03M | -$59.74M | -$37.42M | -$13.42M | — | |
| — | $525 | -$1.05M | -$12.59K | $3.16T | $675.73B | |
| -$10.2M | -$14.03M | -$58.69M | -$37.41M | -$13.42M | -$3.42M | |
| — | -1720.98% | -2325.21% | -63986.48% | — | — | |
| -$10.2M | -$15.53M | -$58.9M | -$37.41M | -$13.52M | -$4.04M | |
| -$10.04M | -$11.2M | -$63.8M | -$35.03M | -$13.42M | — | |
| USD/shares | — | -$828.00 | -$91,169.50 | -$371,662.50 | -$187,000.00 | -$214,200.00 |
| USD/shares | — | -$828.00 | -$91,169.50 | -$371,662.50 | -$187,000.00 | -$214,200.00 |
| shares | — | 18.75K | 646.02 | 100.6551 | 72.185 | 18.8235 |
| shares | — | 18.75K | 646.02 | 100.6551 | 72.185 | 18.8235 |
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 139 similar-size Biotechnology companies (of 545 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Switzerland | $796,590 | $2,437,159 | $58,465 |
| United Kingdom | $18,781 | $23,842 | — |
| United States | — | $63,115 | — |
| Non European Union | — | $23,842 | — |
| European Union | — | $2,437,159 | — |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| License | $600,000 | — | — |
| Other Revenues | $587,882 | — | — |
| Product Sales | $225,835 | $249,028 | — |
| Development Service | $1,654 | $2,275,088 | — |
| Development Services | — | — | $58,465 |